Advertisement

Topics

AQB Reaps A Bounty, CLSN Ends Dual Listing, MNK Opens Wallet, OMER On Watch

01:08 EDT 7 Aug 2017 | RTTNews

Today's Daily Dose brings you news Celsion's decision to end dual listing; MiMedx's progress with AmnioFix Injectable; AquaBounty's improving Q2 financial results; tentative approval from FDA for Perrigo's generic version of rosacea treatment Mirvaso and Mallinckrodt's acquisition of privately-held InfaCare.

Original Article: AQB Reaps A Bounty, CLSN Ends Dual Listing, MNK Opens Wallet, OMER On Watch

NEXT ARTICLE

More From BioPortfolio on "AQB Reaps A Bounty, CLSN Ends Dual Listing, MNK Opens Wallet, OMER On Watch"

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Mirvaso (brimonidine)
MIRVASO® (BRIMONIDINE) TOPICAL GEL, 0.33%* IS THE FIRST & ONLY FDA-APPROVED TREATMENT DEVELOPED AND INDICATED FOR PERSISTENT FACIAL REDNESS OF ROSACEA Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for th...